ViiV's HIV candidate fostemsavir meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) (formerly BMS-663068) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to a significantly greater mean reduction in HIV-1 viral load from baseline to day 8 vs. placebo (0.79 vs. 0.17 log10 copies/mL, p<0.0001). Data were presented at the European AIDS Conference in Milan.

BRIGHTE enrolled 371 patients who failed antiretroviral agents in at least 4 of the 6 available antiretroviral classes and separated patients into a randomized or non-randomized cohort. Secondary endpoints in the double-blind, international trial include durability of response at weeks 24, 48 and 96, safety and emergence of viral resistance...